Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents

• Published in: Scientific reports 2022-01, Vol.12 (1), p.193-193, Article 193
• Main Authors: Yoo, Hae Won, Park, Jun Yong, Kim, Sang Gyune, Jung, Young Kul, Lee, Sae Hwan, Kim, Moon Young, Jun, Dae Won, Jang, Jae Young, Lee, Jin Woo, Kwon, Oh Sang
• Format: Article
• Language: English
• Subjects: 692/4020/4021; 692/699/1503/1607/1605; Administration, Oral; Aged; Antiviral agents; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Carbamates - administration & dosage; Carcinoma, Hepatocellular - diagnosis; Carcinoma, Hepatocellular - epidemiology; Carcinoma, Hepatocellular - prevention & control; Carcinoma, Hepatocellular - virology; Clinical trials; Drug Therapy, Combination; Elasticity Imaging Techniques; Eradication; Female; Fibrosis; Hepatitis C; Hepatitis C, Chronic - diagnosis; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - epidemiology; Hepatitis C, Chronic - virology; Hepatocellular carcinoma; Humanities and Social Sciences; Humans; Imidazoles - administration & dosage; Incidence; Interferon; Interferons - administration & dosage; Isoquinolines - administration & dosage; Liver; Liver cancer; Liver Cirrhosis - diagnostic imaging; Liver Cirrhosis - drug therapy; Liver Cirrhosis - epidemiology; Liver Cirrhosis - virology; Liver Neoplasms - diagnosis; Liver Neoplasms - epidemiology; Liver Neoplasms - prevention & control; Liver Neoplasms - virology; Male; Middle Aged; multidisciplinary; Patients; Prospective Studies; Pyrrolidines - administration & dosage; Retrospective Studies; Ribavirin - administration & dosage; Science; Science (multidisciplinary); Seoul; Sulfonamides - administration & dosage; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine - administration & dosage; Valine - analogs & derivatives
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-03272-1

We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers before treatment and at 48, 96, 144 weeks after starting direct-acting antivirals (DAA) according to the protocol were evaluated. Patients were also compared with historical cohort treated with pegylated interferon (peg-IFN). Sustained viral response (SVR) was observed in 95.8%. LS value in the patients achieving SVR significantly decreased over time (19.4 ± 12.9 kPa [baseline], 13.9 ± 9.1 kPa [48 weeks], 11.7 ± 8.2 kPa [96 weeks], 10.09 ± 6.23 [144 weeks], all p